Pharmacological and non-pharmacological therapy for arrhythmias in the pediatric population: EHRA and AEPC-Arrhythmia Working Group joint consensus statement

Europace

Volumn 15, Issue 9, 2013, Pages 1337-1382

  Brugada, Josep ^a   Blom, Nico ^b   Sarquella Brugada, Georgia ^a   Blomstrom Lundqvist, Carina ^c   Deanfield, John ^d   Janousek, Jan ^e   Abrams, Dominic ^f   Bauersfeld, Urs ^g   Brugada, Ramon ^h   Drago, Fabrizio ⁱ   De Groot, Natasja ^j   Happonen, Juha Matti ^k   Hebe, Joachim ^l   Yen Ho, Siew ^m   Marijon, Eloi ⁿ   Paul, Thomas ^o   Pfammatter, Jean Pierre ^p   Rosenthal, Eric ^q  

^a UNIVERSITY OF BARCELONA   (Spain)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c UPPSALA UNIVERSITY   (Sweden)

^d GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^e UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^f BOSTON CHILDREN S HOSPITAL   (United States)

^g Medizinische Fakultät   (Switzerland)

^h GIRONA BIOMEDICAL RESEARCH INSTITUTE IDIBGI   (Spain)

ⁱ BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^j ERASMUS MEDICAL CENTER   (Netherlands)

^k UNIVERSITY OF HELSINKI AND HELSINKI UNIVERSITY HOSPITAL   (Finland)

^l Center for Electrophysiology Heart Center   (Germany)

^m ROYAL BROMPTON HOSPITAL   (United Kingdom)

ⁿ HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^o UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^p UNIVERSITY OF BERN   (Switzerland)

^q EVELINA LONDON CHILDREN S HOSPITAL   (United Kingdom)

more..

Author keywords

Antiarrhythmic drugs; Arrhythmias; Electrical devices; Paediatrics; Radiofrequency ablation

Indexed keywords

ACEBUTOLOL; ADENOSINE; AMIODARONE; ANTIARRHYTHMIC AGENT; ATENOLOL; AZIMILIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; DIGITALIS; DIGOXIN; DILTIAZEM; DOFETILIDE; ESMOLOL; FLECAINIDE; IBUTILIDE; LIDOCAINE; MAGNESIUM SULFATE; PINDOLOL; PROCAINAIMIDE; PROPAFENONE; PROPRANOLOL; SOTALOL; UNCLASSIFIED DRUG; VERAPAMIL; VERNAKALANT;

ANTIARRHYTHMIC ACTIVITY; ARTICLE; ATRIOVENTRICULAR BLOCK; ATRIOVENTRICULAR CONDUCTION; ATRIOVENTRICULAR NODAL REENTRY TACHYCARDIA; ATRIOVENTRICULAR REENTRY TACHYCARDIA; AV NODAL CONDUCTION BLOCK; BIDIRECTIONAL VENTRICULAR TACHYCARDIA; BLURRED VISION; BRADYCARDIA; BRUGADA SYNDROME; CARDIAC RESYNCHRONIZATION THERAPY; CARDIOVERSION; CATECHOLAMINERGIC POLYMORPHIC VENTRICULAR TACHYCARDIA; CATHETER ABLATION; CHANNELOPATHY; CHILD CARE; CHILDHOOD MORTALITY; CLINICAL EFFECTIVENESS; CONGENITAL HEART BLOCK; CONGENITAL HEART DISEASE; CONGENITAL HEART MALFORMATION; CONSENSUS; CORONARY ARTERY; CRYOABLATION; DEEP SEDATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EXCRETION; DRUG HALF LIFE; DRUG WITHDRAWAL; EBSTEIN ANOMALY; ECTOPIC ATRIAL TACHYCARDIA; ELECTRICAL EQUIPMENT; EPICARDIAL PACEMAKER; EVIDENCE BASED PRACTICE; EXERCISE; EYE TOXICITY; FALLOT TETRALOGY; FASCICULAR VENTRICULAR TACHYCARDIA; FETUS HEART ARRHYTHMIA; FOLLOW UP; FONTAN PROCEDURE; GENETICS; GREAT VESSELS TRANSPOSITION; HEART ACCESSORY CONDUCTION PATHWAY; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART ATRIUM SEPTUM DEFECT; HEART ELECTROPHYSIOLOGY; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE CONDUCTION SYSTEM; HEART PACING; HEART RIGHT VENTRICLE DYSPLASIA; HEART SUPRAVENTRICULAR ARRHYTHMIA; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERACTIVITY; HYPERTROPHIC CARDIOMYOPATHY; HYPOTENSION; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; IRRITABILITY; JUNCTIONAL ECTOPIC TACHYCARDIA; LATE POSTOPERATIVE ARRHYTHMIA; LIFESTYLE; LIVER TOXICITY; LONG QT SYNDROME; LUNG TOXICITY; MENTAL DISEASE; NARROW QRS TACHYCARDIA; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PERMANENT JUNCTIONAL RECIPROCATING TACHYCARDIA; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PSYCHOLOGICAL ASPECT; QRS COMPLEX; QRS TACHYCARDIA; QT INTERVAL; QT PROLONGATION; RADIATION EXPOSURE; RADIOFREQUENCY ABLATION; REENTRY TACHYCARDIA; SAFETY; SECONDARY PREVENTION; SEDATION; SHORT QT SYNDROME; SIDE EFFECT; SINUS NODE; SKIN TOXICITY; SUPRAVENTRICULAR TACHYCARDIA; SYSTEMATIC REVIEW; TACHYCARDIA; THROMBOEMBOLISM; THYROID DISEASE; TORSADE DES POINTES; TREATMENT INDICATION; VALSALVA MANEUVER; VENTRICULAR OUTFLOW TRACT VENTRICULAR TACHYCARDIA; WIDE QRS TACHYCARDIA; WOLFF PARKINSON WHITE SYNDROME;

ANTIARRHYTHMIC DRUGS; ARRHYTHMIAS; ELECTRICAL DEVICES; PAEDIATRICS; RADIOFREQUENCY ABLATION;

ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIAS, CARDIAC; CARDIOLOGY; CARDIOVASCULAR SURGICAL PROCEDURES; CHILD; ELECTRIC COUNTERSHOCK; HUMANS; PEDIATRICS;

EID: 84883437124     PISSN: 10995129     EISSN: 15322092     Source Type: Journal    
DOI: 10.1093/europace/eut082     Document Type: Article

References (332)

1. Lev M. Pathogenesis of congenital atrioventricular block. Prog Cardiovasc Dis 1972;15:145-57.
2. Ho SY, Fagg N, Anderson RH, Cook A, Allan L. Disposition of the atrioventricu-lar conduction tissues in the heart with isomerism of the atrial appendages: its relation to congenital complete heart block. J Am Coll Cardiol 1992;20:904-10.
3. Michaelsson M, Riesenfeld T, Jonzon A. Natural history of congenital complete atrioventricular block. Pacing Clin Electrophysiol 1997;20(8 Part 2):2098-101.
4. Ho SY, Monro JL, Anderson RH. Disposition of the sinus node in left-sided juxtaposition of the atrial appendages. Br Heart J 1979;41:129-32.
5. Ho SY, Anderson RH. Conduction tissue in congenital heart surgery. World J Surg 1985;9:550-67.
6. Hahurij ND, Gittenberger-De Groot AC, Kolditz DP, Bokenkamp R, Schalij MJ. Accessory atrioventricular myocardial connections in the developing human heart: relevance for perinatal supraventricular tachycardias. Circulation 2008; 117:2850-8.
7. Kugler JD, Dandford DA, Houston KA, Felix G. Pediatric radiofrequency catheter ablation registry success, fluoroscopy time, and complication rate for supra-ventricular tachycardia: comparison of early and recent eras. J Cardiovasc Electrophysiol 2002;13:336-41.
8. Van Hare GF, Colan SD, Javitz H, Carmelli D, Knilans T, Schaffer M et al. Prospective assessment after pediatric cardiac ablation: demographics, medical profiles, and initial outcomes. J Cardiovasc Electrophysiol 2004;15:759-70.
9. Santinelli V, Radinovic A, Manguso F, Vicedomini G, Gulletta S, Paglino G et al. The natural history of asymptomatic ventricular pre-excitation a long-term prospective follow-up study of 184 asymptomatic children. J Am Coll Cardiol 2009;53: 275-80.
10. Walsh EP, Saul JP, Hulse JE, Rhodes LA, Hordof AJ, Mayer JE et al. Transcatheter ablation of ectopic atrial tachycardia in young patients using radiofrequency current. Circulation 1992;86:1138-46.
11. Salerno JC, Kertesz NJ, Friedman RA, Fenrich AL Jr. Clinical course of atrial ectopic tachycardia is age-dependent: results and treatment in children, 3 or ≥3 years of age. J Am Coll Cardiol 2004;43:438-44.
12. Collins KK, Van HAre GF, Kertesz NJ, Law IH, Bar-Cohen Y, Dubin AM et al. Pediatric nonpost-operative junctional ectopic tachycardia medical management and interventional therapies. J Am Coll Cardiol 2009;53:690-7.
13. Nanthakumar K, Lau YR, Plumb YJ, Epstein AE, Kay GN. Electrophysiological findings in adolescents with atrial fibrillation who have structurally normal hearts. Circulation 2004;110:117-23.
14. Morwood JG, Triedman JK, Berul CI, Khairy P, Alexander ME, Cecchin F et al. Radiofrequency catheter ablation of ventricular tachycardia in children and young adults with congenital heart disease. Heart Rhythm 2004;1:301-8.
15. El-Sherif N, Chinushi M, Caref EB, Restivo M. Electrophysiological mechanism of the characteristic electrocardiographic morphology of torsade de pointes tachyarrhythmias in the long-QT syndrome: detailed analysis of ventricular tridi-mensional activation patterns. Circulation 1997;96:4392-9.
16. Cerrone M, Noujaim SF, Tolkacheva EG, Talkachou A, O'Connell R, Berenfeld O et al. Arrhythmogenic mechanisms in a mouse model of catechola-minergic polymorphic ventricular tachycardia. Circ Res 2007;101:1039-48.
17. Dodge-Khatami A et al. Surgical substrates of postoperative junctional ectopic tachycardia in congenital heart defects. J Thorac Cardiovasc Surg 2002;123: 624-30.
18. Yildirim SV, Tokel K, Saygili B, Varan B. The incidence and risk factors of arrhythmias in the early period after cardiac surgery in pediatric patients. Turk J Pediatr 2008;50:549-53.
19. Driscoll DJ, Offord KP, Feldt RH, Schaff HV, Puga FJ, Danielson GK. Five-to fifteen-year follow-up after Fontan operation. Circulation 1992;85:469-96.
20. Bink-Boelkens MT, Bergstra A, Landsman ML. Functional abnormalities of the conduction system in children with an atrial septal defect. Int J Cardiol 1988; 20:263-72.
21. Cambien F, Richard JL, Ducimetiere P. Sports activity, paternal history, and the risk of coronary-heart disease. N Engl J Med 1980;303:887.
22. Friedlander Y, Siscovick DS, Argogast P, Psaty BM, Weinmann S, Lemaitre RN et al. Sudden death and myocardial infarction in first degree relatives as predictors of primary cardiac arrest. Atherosclerosis 2002;162:211-6.
23. Dekker LR, Bezzina CR, Henriques JP, Tanck MW, Koch KT, Alings MW et al. Familial sudden death is an important risk factor for primary ventricular fibrillation: a case-control study in acute myocardial infarction patients. Circulation 2006;114:1140-5.
24. Lehnart SE, Ackerman MJ, Benson DW, Brugada R, Clancy CE, Donahue JK et al. Inherited arrhythmias: a National Heart, Lung, and Blood Institute and Office of Rare Diseases workshop consensus report about the diagnosis, phenotyping, molecular mechanisms, and therapeutic approaches for primary cardiomyop-athies of gene mutations affecting ion channel function. Circulation 2007;116: 2325-45.
25. Mitten MJ, Maron BJ, Zipes DP. Task Force 12: legal aspects of the 36th Bethesda Conference recommendations. J Am Coll Cardiol 2005;45:1373-5.
26. Maron BJ. Hypertrophic cardiomyopathy: an important global disease. Am J Med 2004;116:63-5.
27. Wang L, Seidman JG, Seidman CE. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med 2010;152:513-20, W181.
28. Marian AJ. Hypertrophic cardiomyopathy: from genetics to treatment. Eur J Clin Invest 2010;40:360-9.
29. Konno T, Chang S, Seidman JG, Seidman CE. Genetics of hypertrophic cardio-myopathy. Curr Opin Cardiol 2010.
30. Wang H, Li Z, Wang J, Sun K, Cui Q, Song L et al. Mutations in NEXN, a Z-disc gene, are associated with hypertrophic cardiomyopathy. Am J Hum Genet 2010; 87:687-93.
31. Berger S, Dhala A, Dearani JA. State-of-the-art management of hypertrophic cardiomyopathy in children. Cardiol Young 2009;19(Suppl 2):66-73.
32. Marcus FI, McKenna WJ, Sherrill D, Basso C, Bauce B et al. Diagnosis of arrhyth-mogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Circulation 2010;121:1533-41.
33. Awad MM, Calkins H, Judge DP. Mechanisms of disease: molecular genetics of arrhythmogenic right ventricular dysplasia/cardiomyopathy. Nat Clin Pract Cardi-ovasc Med 2008;5:258-67.
34. Azaouagh A, Churzidse S, Konorza T, Erbel R. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: a review and update. Clin Res Cardiol 2010;100: 383-94.
35. Wever-Pinzon OE, Myerson M, Sherrid MV. Sudden cardiac death in young competitive athletes due to genetic cardiac abnormalities. Anadolu Kardiyol Derg 2009;9(Suppl 2):17-23.
36. Schwartz PJ. Cardiac sympathetic innervation and the sudden infant death syndrome. A possible pathogenetic link. Am J Med 1976;60:167-72.
37. Maron BJ, Clark CE, Goldstein RE, Epstein SE. Potential role of QT interval prolongation in sudden infant death syndrome. Circulation 1976;54:423-30.
38. Klaver EC, Versluijs GM, Wilders R. Cardiac ion channel mutations in the sudden infant death syndrome. Int J Cardiol 2011;152:162-70.
39. Tester DJ, Ackerman MJ. Cardiomyopathic and channelopathic causes of sudden unexplained death in infants and children. Annu Rev Med 2009;60:69-84.
40. Schimpf R, Veltmann C, Wolpert C, Borggrefe M. Channelopathies: Brugada syndrome, long QT syndrome, short QT syndrome, and CPVT. Herz 2009;34: 281-8.
41. Tester DJ, Benton AJ, Train L, Deal B, Baudhuin LM, Ackerman MJ. Prevalence and spectrum of large deletions or duplications in the major long QT syndrome-susceptibility genes and implications for long QT syndrome genetic testing. Am J Cardiol 2010;106:1124-8.
42. Kapplinger JD, Tester DJ, Salisbury BA, Carr JL, Harris-Kerr C, Pollevick GD et al. Spectrum and prevalence of mutations from the first 2, 500 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test. Heart Rhythm 2009;6:1297-303.
43. Chen S, Zhang L, Bryant RM, Vincent GM, Flippin M, Lee JC, Brown E et al. KCNQ1 mutations in patients with a family history of lethal cardiac arrhythmias and sudden death. Clin Genet 2003;63:273-82.
44. Bellocq C, van Ginneken AC, Bezzina CR, Alders M, Escande D, Mannens MM et al. Mutation in the KCNQ1 gene leading to the short QT-interval syndrome. Circulation 2004;109:2394-7.
45. Curran ME, Splawski I, Timothy KW, Vincent GM, Green ED, Keating MT. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome. Cell 1995;80:795-803.
46. January CT, Gong Q, Zhou Z. Long QT syndrome: cellular basis and arrhythmia mechanism in LQT2. J Cardiovasc Electrophysiol 2000;11:1413-8.
47. Bianchi L, Shen Z, Dennis AT, Priori SG, Napolitano C, Ronchetti E et al. Cellular dysfunction of LQT5-minK mutants: abnormalities of IKs, IKr and trafficking in long QT syndrome. Hum Mol Genet 1999;8:1499-507.
48. Tsuboi M, Antzelevitch C. Cellular basis for electrocardiographic and arrhythmic manifestations of Andersen-Tawil syndrome (LQT7). Heart Rhythm 2006;3: 328-35.
49. Mohler PJ. Ankyrins and human disease: what the electrophysiologist should know. J Cardiovasc Electrophysiol 2006;17:1153-9.
50. Mohler PJ, Bennett V. Ankyrin-based cardiac arrhythmias: a new class of channe-lopathies due to loss of cellular targeting. Curr Opin Cardiol 2005;20:189-93.
51. Mohler PJ, Schott JJ, Gramolini AO, Dilly KW, Guatimosim S, duBell WH et al. Ankyrin-B mutation causes type 4 long-QT cardiac arrhythmia and sudden cardiac death. Nature 2003;421:634-9.
52. Yang Y, Yany Y, Liang B, Liu J, Li J, Grunnet M et al. Identification of a Kir3.4 mutation in congenital long QT syndrome. Am J Hum Genet 2010;86:87.
53. Schwartz PJ, Priori SG, Locati EH, Napolitano C, Cantu F, Towbin JA et al. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation 1995;92:3381-6.
54. Wang Q, Shen J, Splawski I, Atkinson D, Li Z, Robinson JL et al. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell 1995;80:805-11.
55. Medeiros-Domingo A, Kaku T, Tester DJ, Iturralde-Torres P, Itty A, Ye B et al. SCN4B-encoded sodium channel beta4 subunit in congenital long-QT syndrome. Circulation 2007;116:134-42.
56. Ueda K, Valdivia C, Medeiros-Domingo A, Tester DJ, Vatta M, Farrugia G et al. Syntrophin mutation associated with long QT syndrome through activation of the nNOS-SCN5A macromolecular complex. Proc Natl Acad Sci USA 2008; 105:9355-60.
57. Wu G, Ai T, Kim JJ, Mohapatra B, Xi Y, Li Z et al. alpha-1-syntrophin mutation and the long-QT syndrome: a disease of sodium channel disruption. Circ Arrhythm Electrophysiol 2008;1:193-201.
58. Vatta M, Ackerman MJ, Ye B, Makielski JC, Ughanze EE, Taylor EW et al. Mutant caveolin-3 induces persistent late sodium current and is associated with long-QT syndrome. Circulation 2006;114:2104-12.
59. Splawski I, Timothy KW, Sharpe LM, Decher N, Kumnar P, Bloise R et al. Ca(V)1.2 calcium channel dysfunction causes a multisystem disorder including arrhythmia and autism. Cell 2004;119:19-31.
60. Yarotskyy V, Gao G, Peterson BZ, Elmslie KS. The Timothy syndrome mutation of cardiac CaV1.2 (L-type) channels: multiple altered gating mechanisms and pharmacological restoration of inactivation. J Physiol 2009;587(Part 3):551-65.
61. Kauferstein S, Kiehne N, Erkapic D, Schmidt J, Hamn CW, Brastzke H et al. A novel mutation in the cardiac ryanodine receptor gene (RyR2) in a patient with an unequivocal LQTS. Int J Cardiol 2011;146:249-50.
62. Chen L, Marquardt ML, Tester DJ, Sampson KJ, Ackerman MJ, Kass RD. Mutation of an A-kinase-anchoring protein causes long-QT syndrome. Proc Natl Acad Sci USA 2007;104:20990-5.
63. Gussak I, Brugada P, Brugada J, Wright RS, Kopecky SL, Chaitman BR et al. Idio-pathic short QT interval: a new clinical syndrome? Cardiology 2000;94:99-102.
64. Morita H, Wu J, DP Zipes J. The QT syndromes: long and short. Lancet 2008; 372:750-63.
65. Crotti L, Taravelli E, Girardengo G, Schwartz PJ. Congenital short QT syndrome. Indian Pacing Electrophysiol J 2010;10:86-95.
66. Bjerregaard P, Nallapaneni H, Gussak I. Short QT interval in clinical practice. J Electrocardiol 2010;43:390-5.
67. Triedman JK. Brugada and short QT syndromes. Pacing Clin Electrophysiol 2009; 32(Suppl 2):S58-62.
68. Zareba W, Cygankiewicz I. Long QT syndrome and short QT syndrome. Prog Cardiovasc Dis 2008;51:264-78.
69. Patel U, Pavri BB. Short QT syndrome: a review. Cardiol Rev 2009;17:300-3.
70. Patel C, Yan GX, Antzelevitch C. Short QT syndrome: from bench to bedside. Circ Arrhythm Electrophysiol 2010;3:401-8.
71. Brugada R, Hong K, Dumaine R, Cordeiro J, Gaita F, Borggrefe M et al. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 2004;109:30-5.
72. Hong K, Bjerregaard P, Gussak I, Brugada R. Short QT syndrome and atrial fibrillation caused by mutation in KCNH2. J Cardiovasc Electrophysiol 2005;16: 394-6.
73. Hong K, Piper DR, Diaz-Valdecantos A, Brugada J, Oliva A, Burashnikov E et al. De novo KCNQ1 mutation responsible for atrial fibrillation and short QT syndrome in utero. Cardiovasc Res 2005;68:433-40.
74. Priori SG, Pandit SV, Rivolta I, Berenfeld O, Ronchetti E, Dhamoon A et al. A novel form of short QT syndrome (SQT3) is caused by a mutation in the KCNJ2 gene. Circ Res 2005;96:800-7.
75. Templin C, Ghadri JR, Rougier JS, Baumer A, Kaplan V, Albesa M et al. Identification of a novel loss-of-function calcium channel gene mutation in short QT syndrome (SQTS6). Eur Heart J 2011;32:1077-88.
76. Brugada P, Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol 1992;20:1391-6.
77. Campuzano O, Brugada R, Iglesias A. Genetics of Brugada syndrome. Curr Opin Cardiol 2010;25:210-5.
78. Kapplinger JD, Tester DJ, Alders M, Benito B, Berthet M, Brugada J et al. An international compendium of mutations in the SCN5A-encoded cardiac sodium channel in patients referred for Brugada syndrome genetic testing. Heart Rhythm 2010;7:33-46.
79. London B, Michalec M, Mehdi H, Zhu X, Kerchner L, Sanyal S et al. Mutation in glycerol-3-phosphate dehydrogenase 1 like gene (GPD1-L) decreases cardiac Na+ current and causes inherited arrhythmias. Circulation 2007;116:2260-8.
80. Van Norstrand DW, Aldiva CR, Tester DJ, Ueda K, London B, Malielski JC et al. Molecular and functional characterization of novel glycerol-3-phosphate de-hydrogenase 1 like gene (GPD1-L) mutations in sudden infant death syndrome. Circulation 2007;116:2253-9.
81. Watanabe H, Koopmann TT, Le Scouarnec S, Yang T, Ingram CR, Schott JJ et al. Sodium channel beta1 subunit mutations associated with Brugada syndrome and cardiac conduction disease in humans. J Clin Invest 2008;118:2260-8.
82. Hu D, Barajas-Martinez H, Burashnikov E, Springer M, Wu Y, Varro A et al. A mutation in the beta 3 subunit of the cardiac sodium channel associated with Brugada ECG phenotype. Circ Cardiovasc Genet 2009;2:270-8.
83. Delpon E, Cordeiro JM, Nunez L, Thomsen PE, Guerchicoff A, Pollevick GD et al. Functional effects of KCNE3 mutation and its role in the development of Brugada syndrome. Circ Arrhythm Electrophysiol 2008;1:209-18.
84. Ueda K, Hirano Y, Higashiuesato Y, Aizawa Y, Hayashi T, Inagaki N et al. Role of HCN4 channel in preventing ventricular arrhythmia. J Hum Genet 2009;54:115-21.
85. Haissaguerre M, CHatel S, Sacher F, Weerasooriya R, Probst V, Loussouarn G et al. Ventricular fibrillation with prominent early repolarization associated with a rare variant of KCNJ8/KATP channel. J Cardiovasc Electrophysiol 2009;20: 93-8.
86. Medeiros-Domingo A, Tan BH, Crotti L, Tester DJ, Eckhardt L, Cuoretti A et al. Gain-of-function mutation S422L in the KCNJ8-encoded cardiac K(ATP) channel Kir6.1 as a pathogenic substrate for J-wave syndromes. Heart Rhythm 2010;7: 1466-71.
87. Kattygnarath D, Maugenre S, Neyroud N, Balse E, Ichai C, Denjoy I et al. MOG1: a new susceptibility gene for Brugada syndrome. Circ Cardiovasc Genet 2011;4: 261-8.
88. Ohno S, Zankov DP, Ding WG, Itoh H, Makiyama T, Doi T et al. KCNE5 (KCNE1L) variants are novel modulators of Brugada syndrome and idiopathic ventricular fibrillation. Circ Arrhythm Electrophysiol 2011;4:352-61.
89. Reid DS, Tynan M, Braidwood L, Fitzgerals GR. Bidirectional tachycardia in a child. A study using His bundle electrography. Br Heart J 1975;37:339-44.
90. Celiker A, Ergodan I, Karagoz T, Ozer S. Clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia. Cardiol Young 2009;19: 45-52.
91. Lahat H, Eldar M, Levy-Nissenbaum E, Bahan T, Friedman E, Khoury A et al. Autosomal recessive catecholamine-or exercise-induced polymorphic ventricular tachycardia: clinical features and assignment of the disease gene to chromosome 1p13-21. Circulation 2001;103:2822-7.
92. Tester DJ, Arya P, Will M, Haglund CM, Farley AL, Makielski JC et al. Genotypic heterogeneity and phenotypic mimicry among unrelated patients referred for catecholaminergic polymorphic ventricular tachycardia genetic testing. Heart Rhythm 2006;3:800-5.
93. Tester DJ, Ackerman MJ. Genetic testing for potentially lethal, highly treatable inherited cardiomyopathies/channelopathies in clinical practice. Circulation 2011;123:1021-37.
94. Rutzen-Lopez H, Vkhanna V, Reynolds M. Atrial fibrillation: epidemiology, prognosis and therapy. Minerva Med 2010;102:187-207.
95. Lubitz SA, Yi BA, Ellinor PT. Genetics of atrial fibrillation. Heart Fail Clin 2010;6: 239-47.
96. van der Werf C, van Langen IM, Wilde AA. Sudden death in the young: what do we know about it and how to prevent? Circ Arrhythm Electrophysiol 2010;3: 96-104
97. The Working Group on Arrhythmias of the European Society of Cardiology. Survivors of out-of-hospital cardiac arrest with apparently normal heart. Need for definition and standardized clinical evaluation. Consensus Statement of the Joint Steering Committees of the Unexplained Cardiac Arrest Registry of Europe and of the Idiopathic Ventricular Fibrillation Registry of the United States. Circulation 1997;95:265-72.
98. van der Werf C, Hofman N, Tan HL, van Dessel PF, Alders M, van der Wal AC et al. Diagnostic yield in sudden unexplained death and aborted cardiac arrest in the young: the experience of a tertiary referral center in The Netherlands. Heart Rhythm 2010;7:1383-9.
99. Alders M, Koopmann TT, Christiaans I, Postema PG, Beekman L, Tanck MW et al. Haplotype-sharing analysis implicates chromosome 7q36 harboring DPP6 in familial idiopathic ventricular fibrillation. Am J Hum Genet 2009;84:468-76.
100. Radicke S, Cotella D, Graf EM, Ravens U, Wettwer E. Expression and function of dipeptidyl-aminopeptidase-like protein 6 as a putative beta-subunit of human cardiac transient outward current encoded by Kv4.3. J Physiol 2005;565(Part 3):751-6.
101. Haissaguerre M, Derval N, Sacher F, Jesell L, Deisenhofer I, de Roy L et al. Sudden cardiac arrest associated with early repolarization. N Engl J Med 2008; 358:2016-23.
102. Nam GB, Kim YH, Antzelevitch C. Augmentation of J waves and electrical storms in patients with early repolarization. N Engl J Med 2008;358:2078-9.
103. Rosso R, Kogan E, Belhassen B, Rozovski U, Scheinman MM, Zeltser D et al. J-point elevation in survivors of primary ventricular fibrillation and matched control subjects: incidence and clinical significance. J Am Coll Cardiol 2008;52: 1231-8.
104. Burashnikov E, Pfeiffer R, Barajas-Martinez H, Delpon E, Hu D, Desai M et al. Mutations in the cardiac L-type calcium channel associated with inherited J-wave syndromes and sudden cardiac death. Heart Rhythm 2010;7:1872-82.
105. Miyazaki S, Shah AJ, Haissaguerre M. Early repolarization syndrome-a new electrical disorder associated with sudden cardiac death. Circ J 2010;74:2039-44.
106. Lenegre J, Moreau P. Chronic auriculo-ventricular block. Anatomical, clinical and histological study. Arch Mal Coeur Vaiss 1963;56:867-88.
107. Lev M. Anatomic basis for atrioventricular block. Am J Med 1964;37:742-8.
108. Brink PA, Ferreira A, Moolman JC, Weymar HW, van der Merwe PL, Corfield VA. Gene for progressive familial heart block type I maps to chromosome 19q13. Circulation 1995;91:1633-40.
109. Tan HL, Bink-Boelkens MT, Bezzina CR, Viswanathan PC, Beaufort-Krol GC, van Tintelen PJ et al. A sodium-channel mutation causes isolated cardiac conduction disease. Nature 2001;409:1043-7.
110. Schott JJ, Alshinawi C, Kyndt F, Probst V, Hoorntje TM, Hulsbeek M et al. Cardiac conduction defects associate with mutations in SCN5A. Nat Genet 1999;23:20-1.
111. Schott JJ, Benson DW, Basson CT, Pease W, Silberbach GM, Moak JP, MAron BJ et al. Congenital heart disease caused by mutations in the transcription factor NKX2-5. Science 1998;281:108-11.
112. Liu H, El Zein L, Kruse M, Guinamard R, Beckmann A, Bozio A et al. Gain-of-function mutations in TRPM4 cause autosomal dominant isolated cardiac conduction disease. Circ Cardiovasc Genet 2010;3:374-85.
113. Benson DW, Wang DW, Dyment M, Knilans TK, Fish FA, Strieper MJ et al. Congenital sick sinus syndrome caused by recessive mutations in the cardiac sodium channel gene (SCN5A). J Clin Invest 2003;112:1019-28.
114. Lei M, Huang CL, Zhang Y. Genetic Na+ channelopathies and sinus node dysfunction. Prog Biophys Mol Biol 2008;98:171-8.
115. Makiyama T, Akao M, Tsuji K, Doi T, Ohno S, Takenaka K et al. High risk for bradyarrhythmic complications in patients with Brugada syndrome caused by SCN5A gene mutations. J Am Coll Cardiol 2005;46:2100-6.
116. Smits JP, Koopmann TT, Wilders R, Veldkamp MW, Opthof T, Bhuiyan ZA et al. A mutation in the human cardiac sodium channel (E161K) contributes to sick sinus syndrome, conduction disease and Brugada syndrome in two families. J Mol Cell Cardiol 2005;38:969-81.
117. Veldkamp MW, Wilders R, Baartscheer A, Zegers JG, Bezzina CR, Wilde AA. Contribution of sodium channel mutations to bradycardia and sinus node dysfunction in LQT3 families. Circ Res 2003;92:976-83.
118. Verkerk AO, Wilders R, van Borren MM, Tan HL. Is sodium current present in human sinoatrial node cells? Int J Biol Sci 2009;5:201-4.
119. Sidhu J, Roberts R. Genetic basis and pathogenesis of familial WPW syndrome. Indian Pacing Electrophysiol J 2003;3:197-201.
120. Lalani SR, Thakuria JV, COx GF, Wang X, Bi W, Bray MS et al. 20p12.3 micro-deletion predisposes to Wolff-Parkinson-White syndrome with variable neu-rocognitive deficits. J Med Genet 2009;46:168-75.
121. Ko J, Deal BK, Strasburger JF, Benson DW Jr et al. Supraventricular tachycardia mechanisms and their age distribution in pediatric patients. Am J Cardiol 1992;69: 1028-32.
122. Tipple MA. Usefulness of the electrocardiogram in diagnosing mechanisms of tachycardia. Pediatr Cardiol 2000;21:516-21.
123. Paul T, Pfammatter J-P. Adenosine: an effective and safe antiarrhythmic drug in pediatrics. Pediatr Cardiol 1997;18:118-26.
124. Dixon J, Foster K, Wyllie J, Wren C. Guidelines and adenosine dosing in supra-ventricular tachycardia. Arch Dis Child 2005;90:1190-1.
125. Jaeggi ET, Carvalho JS, De Groot E, Api O, Clur SA Rammmeloo L et al. Comparison of transplacental treatment of fetal supraventricular tachyarrhythmias with digoxin, flecainide, and sotalol: results of a nonrandomized multicenter study. Circulation 2011;124:1747-54.
126. Van Hare GF, Lesh MD, Ross BA, Perry JC, Dorostkar PC. Mapping and radio-frequency ablation of intraatrial reentrant tachycardia after the Senning or Mustard procedure for transposition ofthe great arteries. Am J Cardiol 1996; 77:985-91.
127. Porter CJ, Garson A Jr, Gillette PC. Verapamil: an effective calcium blocking agent for pediatric patients. Pediatrics 1983;71:748-55.
128. Weindling SN, Saul JP, Walsh EP. Efficacy and risks of medical therapy for supra-ventricular tachycardia in neonates and infants. Am Heart J 1996;131:66-72.
129. Lemler MS, Schaffer MS. Neonatal supraventricular tachycardia: predictors of successful treatment withdrawal. Am Heart J 1997;133:130-1.
130. Price JF, Kertesz NJ, Snyder CS, Friedman RA, Fenrisch AL. Flecainide and sotalol: a new combination therapy for refractory supraventricular tachycardia in children, 1 year of age. J Am Coll Cardiol 2002;39:517-20.
131. Riggs TW, Byrd JA, Weinhouse E. Recurrence Risk of Supraventricular Tachycardia in Pediatric Patients. Cardiology 1999;91:25-30.
132. Alboni P, Brignole M, Menozzi C, Raviele A, Del Rosso A, Dinelli M et al. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia. J Am Coll Cardiol 2001;37:548-53.
133. Brady PA, Low PA, Shen WK. Inappropriate sinus tachycardia, postural ortho-static tachycardia syndrome, and overlapping syndromes. Pacing Clin Electrophysiol 2005;28:1112-21.
134. Blaufox AD, Saul JP. Radiofrequency ablation of right-sided accessory pathways in pediatric patients. Prog Pediatr Cardiol 2001;13:25-40.
135. Crosson JE, Hesslein PS, Thilenus OG, Dunnigan Al. AV node reentry tachycardia in infants. Pacing Clinl Electrophysiol 1995;18:2144-9.
136. Mehta A, Subrahmanyam A, Anand R. Long-term efficacy and safety of atenolol for supraventricular tachycardia in children. Pediatr Cardiol 1996;17:231-6.
137. Probst V, Denjoy I, Meregalli PG, Amirault JC, Sacher F, Mansourati J et al. Clinical aspects and prognosis of Brugada syndrome in children. Circulation 2007;115: 2042-8.
138. Brugada J, Closas R, Ordonez A, Mabrok M, Grecu M, Merce J et al. Radiofre-quency catheter ablation of an incessant supraventricular tachycardia in a premature neonate. Pacing Clin Electrophysiol 2002;25:866-8.
139. Lindinger A, Heisel A, von Bernuth G, Paul T, Ulmer H, Kienast W et al. Permanent junctional re-entry tachycardia. A multicentre long-term follow-up study in infants, children and young adults. Eur Heart J 1998;19:936-42.
140. Vaksmann G, D'Hoinne C, Lucet V, Guillaumont S, Lupoglazoff JM, Chantepie A et al. Permanent junctional reciprocating tachycardia in children: a multicentre study on clinical profile and outcome. Heart 2006;92:101-4.
141. Deal BJ, Keane JF, Gillette PC, Garson A Jr. Wolff-Parkinson-White syndrome and supraventricular tachycardia during infancy: management and follow-up. J Am Coll Cardiol 1985;5:130-5.
142. Tortoriello T, Snyder CS, Smith EO, Fenrich AL Jr, Friedman RA, Kertesz NJ et al. Frequency of recurrence among infants with supraventricular tachycardia and comparison of recurrence rates among those with and without preexcita-tion and among those with and without response to digoxin and/or propranolol therapy. Am J Cardiol 2003;92:1045-9.
143. Perry JC, Garson A Jr. Supraventricular tachycardia due to Wolff-Parkinson-White syndrome in children: early disappearance and late recurrence. J Am Coll Cardiol 1990;16:1215-20.
144. Morrison TB, Rea RF, Hodge DO, Crusan D, Koestler C, Asirvathan SJ et al. Risk factors for implantable defibrillator lead fracture in a recalled and a nonrecalled lead. J Cardiovasc Electrophysiol 2010;21:671-7.
145. Bromberg BI, Lindsay BD, Cain ME, Cox JL et al. Impact of clinical history and electrophysiologic characterization of accessory pathways on management strategies to reduce sudden death among children with Wolff-Parkinson-White syndrome. J Am Coll Cardiol 1996;27:690-5.
146. Kistler PM, Sanders P, Fynn SP, Stevenson IH, Hussin A, Vohra JK et al. Electro-physiological and electrocardiographic characteristics of focal atrial tachycardia originating from the pulmonary veins: acute and long-term outcomes of radio-frequency ablation. Circulation 2003;108:1968-75.
147. Kugler JD, Danford DA, Houston K, Felix G et al. Radiofrequency catheter ablation for paroxysmal supraventricular tachycardia in children and adolescents without structural heart disease. Am J Cardiol 1997;80:1438-43.
148. Friedman RA, Walsh EP, Silka MJ, Calkins H, Stevenson WG, Rhodes LA et al. NASPE Expert Consensus Conference: Radiofrequency catheter ablation in children with and without congenital heart disease. Report of the writing committee. North American Society of Pacing and Electrophysiology. Pacing Clin Electrophysiol 2002;25:1000-17.
149. Schaffer MS, Gow RM, Moak JP, Saul JP. Mortality following radiofrequency catheter ablation (from the Pediatric Radiofrequency Ablation Registry). Participating members of the Pediatric Electrophysiology Society. Am J Cardiol 2000;86: 639-43.
150. Joung B, Lee M, Sung JH, Kim JY, Ahn S, Kim S. Pediatric radiofrequency catheter ablation. Circ J 2006;70:278-84.
151. Janousek J, Paul T. Safety of oral propafenone in the treatment of arrhythmias in infants and children (European retrospective multicenter study). Working Group on Pediatric Arrhythmias and Electrophysiology of the Association of European Pediatric Cardiologists. Am J Cardiol 1998;81:1121-4.
152. Kishore AGR, Camm AJ. Guidelines for the use of propafenone in treating supraventricular arrhythmias. Drugs 1995;50:250-62.
153. Janousek J, Paul T, Reimer A, Kallfelz HC. Usefulness of propafenone for supra-ventricular arrhythmias in infants and children. Am J Cardiol 1993;72:294-300.
154. Heusch A, Kramer HH, Krogmann ON, Rammos S, Bourgeous M. Clinical experience with propafenone for cardiac arrhythmias in the young. Eur Heart J 1994;15:1050-6.
155. Perry JC, Garson A Jr. Flecainide acetate for treatment of tachyarrhythmias in children: review of world literature on efficacy, safety, and dosing. Am Heart J 1992;124:1614-21.
156. Núñez F, Ruiz-GRanell R, Martinez-Costa C, Morell S, Brines J. Safety and efficacy of flecainide in the treatment of symptomatic children with Wolff-Parkinson-White Syndrome. Pediatr Cardiol 2010;31:1162-5.
157. Pfammatter JP, Paul T, Lehman C, Kallfelz HC. Efficacy and proarrhythmia of oral sotalol in pediatric patients. J Am Coll Cardiol 1995;26:1002-7.
158. Laer S, Elshoff JP, Meibohm B, Weil J, Mir TS, Zhang W et al. Development of a safe and effective pediatric dosing regimen for sotalol based on population pharmacokinetics and pharmacodynamics in children with supraventricular tachycardia. J Am Coll Cardiol 2005;46:1322-30.
159. Etheridge SP, Sanatani S, Cohen MI, Albaro CA, Saarel EV, Bradley DJ. Long QT syndrome in children in the era of implantable defibrillators. J Am Coll Cardiol 2007;50:1335-40.
160. Pfammatter JP, Bauersfeld U. Safety issues in the treatment of paediatric supra-ventricular tachycardias. Drug Saf 1998;18:345-56.
161. Stambach D, Bernet V, Bauersfeld U. Clinical recognition and treatment of atrial ectopic tachycardia in newborns. Swiss Med Wkly 2007;137:402-6.
162. Fish FA, Gillette PC, Benson DW Jr. Proarrhythmia, cardiac arrest and death in young patients receiving encainide and flecainide. The Pediatric Electrophysi-ology Group. J Am Coll Cardiol 1991;18:356-65.
163. Texter KM, Kertesz NJ, Friedman RA, Fenrich AL Jr. Atrial flutter in infants. J Am Coll Cardiol 2006;48:1040-6.
164. Casey FA, McCrindle BW, Hamilton RM, Gow RM. Neonatal atrial flutter: significant early morbidity and excellent long-term prognosis. Am Heart J 1997; 133:302-6.
165. Garson A Jr, Dick M 2nd, Fournier A, Gillette PC, Hamilton R, Kugler JD et al. The long QT syndrome in children. An international study of 287 patients. Circulation 1993;87:1866-72.
166. Moss AJ, Zareba W, Hall WJ, Schwartz PJ, Crampton RS, Benhorin J et al. Effectiveness and limitations of beta-blocker therapy in congenital long-QT syndrome. Circulation 2000;101:616-23.
167. Moss AJ, Windle JR, Hall WJ, Zareba W, Robinson JL, McNitt S et al. Safety and efficacy of flecainide in subjects with long QT-3 syndrome (DeltaKPQ mutation): a randomized, double-blind, placebo-controlled clinical trial. Ann Noninvasive Electrocardiol 2005;10(4 Suppl):59-66.
168. Webster G, Berul CI. Congenital long-QT syndromes: a clinical and genetic update from infancy through adulthood. Trends Cardiovasc Med 2008;18:216-24.
169. Kaufman ES. Mechanisms and clinical management of inherited channelopathies: long QT syndrome, Brugada syndrome, catecholaminergic polymorphic ventricular tachycardia, and short QT syndrome. Heart Rhythm 2009;6(8 Suppl): S51-5.
170. De Rosa G, Delogu AB, Piastra M, Chiaretti A, Bloise R, Priori SG et al. Catecho-laminergic polymorphic ventricular tachycardia: successful emergency treatment with intravenous propranolol. Pediatr Emerg Care 2004;20:175-7.
171. Watanabe H, Chopra N, Laver D, Hwang HS, Davies SS, Roach DE et al. Flecai-nide prevents catecholaminergic polymorphic ventricular tachycardia in mice and humans. Nat Med 2009;15:380-3.
172. Kavey RE, Blackman MS, Sondheimer HM, Byrum CJ. Ventricular arrhythmias and mitral valve prolapse in childhood. J Pediatr 1984;105:885-90.
173. Huehnergarth KV, Gurvitz M, Stout KK, Otto CM. Repaired tetralogy of Fallot in the adult: monitoring and management. Heart 2008;94:1663-9.
174. Schwerzmann M, Salehian O, Harris L, Siu SC, Willimas WG, Webb GD et al. Ventricular arrhythmias and sudden death in adults after a Mustard operation for transposition of the great arteries. Eur Heart J 2009;30:1873-9.
175. Abrams DJ et al. Comparison of noncontact and electroanatomic mapping to identify scar and arrhythmia late after the Fontan procedure. Circulation 2007; 115:1738-46.
176. Kugler JD, Danford DA, Deal BJ, Gillette PC, Perry JC, Silka MJ et al. Radiofre-quency catheter ablation for tachyarrhythmias in children and adolescents. N Engl J Med 1994;330:1481-7.
177. Gatzoulis MA, Balaji S, Webber SA, Siu SC, Hokanson JS, Poile C et al. Risk factors for arrhythmia and sudden cardiac death late after repair of tetralogy of Fallot: a multicentre study. Lancet 2000;356:975-81.
178. Khairy P, Stevenson WG. Catheter ablation in tetralogy of Fallot. Heart Rhythm 2009;6:1069-74.
179. Zeppenfeld K, Schalij MJ, Bartelings MM, Tedrow UB, Koplan BA, Soejima K et al. Catheter ablation of ventricular tachycardia after repair of congenital heart disease: electroanatomic identification of the critical right ventricular isthmus. Circulation 2007;116:2241-52.
180. Fouron JC. Fetal arrhythmias: the Saint-Justine hospital experience. Prenat Diagn 2004;24:1068-80.
181. Zhao H, Cuneo BF, Strasburger JF, Huhta JC, Gotteiner NL, Wakai RT. Electro-physiological characteristics of fetal atrioventricular block. J Am Coll Cardiol 2008; 51:77-84.
182. Skog A, Wahren-Herlenius M, Sundstrom B, Bremme K, Sonesson SE. Outcome and growth of infants fetally exposed to heart block-associated maternal anti-Ro52/SSA autoantibodies. Pediatrics 2008;121:e803-9.
183. Kugler JD, Danford DA. Management of infants, children, and adolescents with paroxysmal supraventricular tachycardia. J Pediatr 1996;129:324-38.
184. Webb CL, Dick M 2nd, Rocchini AP, Snider AR, Crowley DC, Beekman RH et al. Quinidine syncope in children. J Am Coll Cardiol 1987;9:1031-7.
185. Vignati G, Mauri L, Figini A. The use of propafenone in the treatment of tachyar-rhythmias in children. Eur Heart J 1993;14:546-50.
186. Robertson CE, Miller HC. Extreme tachycardia complicating the use of disopyr-amide in atrial flutter. Br Heart J 1980;44:602-3.
187. Taylor DC, Falconer MA, Flor-Henry P. Some evidence of bilateral speech representation in sinistrals. Clin EEG Neurosci 2010;41:214-8.
188. Fujiki A, Usui M, Nagasawa H, Mizumaki K, Hayashi H, Inoue H. ST segment elevation in the right precordial leads induced with class IC antiarrhythmic drugs: insight into the mechanism of Brugada syndrome. J Cardiovasc Electrophysiol 1999;10:214-8.
189. Reimer A, Paul T, Kallfelz HC. Efficacy and safety of intravenous and oral propa-fenone in pediatric cardiac dysrhythmias. Am J Cardiol 1991;68:741-4.
190. Perry JC, Garson A Jr. Flecainide acetate for resistant arrhythmias in the young: efficacy and pharmacokinetics. J Am Coll Cardiol 1989;14:185-91; discussion 192-3.
191. Billman GE, Castillo LC, Hensley J, Hohl CM, Altschuld RA. Beta2-adrenergic receptor antagonists protect against ventricular fibrillation: in vivo and in vitro evidence for enhanced sensitivity to beta2-adrenergic stimulation in animals susceptible to sudden death. Circulation 1997;96:1914-22.
192. Trippel DL, Gillette PC. Atenolol in children with supraventricular tachycardia. Am J Cardiol 1989;64:233-6.
193. Goldschlager N, Epstein AE, Naccarelli G, Olshansky B, Singh B. Practical guidelines for clinicians who treat patients with amiodarone. Practice Guidelines Subcommittee, North American Society of Pacing and Electrophysiology. Arch Intern Med 2000;160:1741-8.
194. Pfammatter J-P, Paul T. New antiarrhythmic drug in pediatric use: sotalol. Pediatr Cardiol 1997;18:28-34.
195. Hohnloser SH, Klingenheben T, Singh BN. Amiodarone-associated proarrhyth-mic effects. A review with special reference to torsade de pointes tachycardia. Ann Intern Med 1994;121:529-35.
196. Ng GY, Hampson Evans DC, Murdoch LJ. Cardiovascular collapse after amiodar-one administration in neonatal supraventicular tachycardia. Eur J Emerg Med 2003;10:323-5.
197. Paul T, Guccione P. New antiarrhythmic drugs in pediatric use: amiodarone. Pediatr Cardiol 1994;15:132-8.
198. Vorperian Md FVR, Havighurst TC, Miller S, January CT. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997;30:791-8.
199. Guccione P, Paul T, Garson A Jr. Long-term follow-up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects. J Am Coll Cardiol 1990;15:1118-24.
200. Coumel P, Fidelle J. Amiodarone in the treatment of cardiac arrhythmias in children: one hundred thirty-five cases. Am Heart J 1980;100(6 Part 2):1063-9.
201. Le Heuzey JY, De Ferrari GM, Radzik D, Santini M, Zhu J, Davy JM. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol 2010;21:597-605.
202. Epstein ML, Kiel EA, Victorica BE. Cardiac decompensation following verapamil therapy in infants with supraventricular tachycardia. Pediatrics 1985;75:737-40.
203. Till J, Shinebourne EA, Rigby ML, Clarke B, Ward DE, Rowland E. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J 1989;62:204-11.
204. DeGroff CG, Silka MJ. Bronchospasm after intravenous administration of adeno-sine in a patient with asthma. J Pediatr 1994;125(5 Part 1):822-3.
205. Hauptman PJ, Kelly RA. Digitalis. Circulation 1999;99:1265-70.
206. Byrum CJ, Wahl RA, Behrendt DM, Dick M. Ventricular fibrillation associated with use of digitalis in a newborn infant with Wolff-Parkinson-White syndrome. J Pediatr 1982;101:400-3.
207. Morady F. Radio-frequency ablation as treatment for cardiac arrhythmias. N Engl J Med 1999;340:534-44.
208. Fitzpatrick AP, Gonzales RP, Lesh MD, Modin GW, Lee RJ, Scheinman MM. New algorithm for the localization of accessory atrioventricular connections using a baseline electrocardiogram. J Am Coll Cardiol 1994;23:107-16.
209. Haissaguerre M et al. Electrogram patterns predictive of successful catheter ablation of accessory pathways. Value of unipolar recording mode. Circulation 1991;84:188-202.
210. Saul JP, Hulse JE, De W, Weber AT, Rhodes LA, Lock JE et al. Catheter ablation of accessory atrioventricular pathways in young patients: use of long vascular sheaths, the transseptal approach and a retrograde left posterior parallel approach. J Am Coll Cardiol 1993;21:571-83.
211. Schaffer MS, Silka MJ, Ross BA, Kugler JD. Inadvertent atrioventricular block during radiofrequency catheter ablation. Results of the Pediatric Radiofrequency Ablation Registry. Pediatric Electrophysiology Society. Circulation 1996;94: 3214-20.
212. Tuzcu V. A nonfluoroscopic approach for electrophysiology and catheter ablation procedures using a three-dimensional navigation system. Pacing Clin Electro-physiol 2007;30:519-25.
213. Gaita F, Haissaguerre M, Giustetto C, Fischer B, Riccardi R, Richiardi E et al. Catheter ablation of permanent junctional reciprocating tachycardia with radiofrequency current. J Am Coll Cardiol 1995;25:648-54.
214. Aguinaga L, Primo J, Anguera I, Mont L, Valnetino M, Brugada P et al. Long-term follow-up in patients with the permanent form of junctional reciprocating tachycardia treated with radiofrequency ablation. Pacing Clin Electrophysiol 1998;21(11 Part 1):2073-8.
215. Jackman WM, Beckman KJ, McClelland JH, Wang X, Friday KJ, Roman CA et al. Treatment of supraventricular tachycardia due to atrioventricular nodal reentry, by radiofrequency catheter ablation of slow-pathway conduction. N Engl J Med 1992;327:313-8.
216. Pfammatter JP, Paul T. Idiopathic ventricular tachycardia in infancy and childhood: a multicenter study on clinical profile and outcome. Working Group on Dysrhythmias and Electrophysiology of the Association for European Pediatric Cardiology. J Am Coll Cardiol 1999;33:2067-72.
217. Schneider HE, Kriebel T, Jung K, Gravenhorst VD, Paul T. Catheter ablation of idiopathic left and right ventricular tachycardias in the pediatric population using noncontact mapping. Heart Rhythm 2010;7:731-9.
218. Gonzalezy Gonzalez MB, Will JC, Tuzcu V, Schranz D, Blaufox AD, Saul JP et al. Idiopathic monomorphic ventricular tachycardia originating from the left aortic sinus cusp in children: endocardial mapping and radiofrequency catheter ablation. Z Kardiol 2003;92:155-63.
219. Van Hare GF, Colan SD, Javitz H, Carmelli D, Knilans T, Schaffer M et al. Prospective assessment after pediatric cardiac ablation: fate of intracardiac structure and function, as assessed by serial echocardiography. Am Heart J 2007;153: 815-20, 820 e1-6.
220. Drago F. Paediatric catheter cryoablation: techniques, successes and failures. Curr Opin Cardiol 2008;23:81-4.
221. Zhou L, Keane D, Reed G, Ruskin J. Thromboembolic complications of cardiac radiofrequency catheter ablation: a review of the reported incidence, pathogen-esis and current research directions. J Cardiovasc Electrophysiol 1999;10:611-20.
222. Paul T, Bokenkamp R, Mahnert B, Trappe HJ. Coronary artery involvement early and late after radiofrequency current application in young pigs. Am Heart J 1997; 133:436-40.
223. Schneider HE, Kriebel T, Gravenhorst VD, Paul T. Incidence of coronary artery injury immediately after catheter ablation for supraventricular tachycardias in infants and children. Heart Rhythm 2009;6:461-7.
224. Aiyagari R, Saarel EV, Etheridge SP, Bradley DJ, Dick M 2nd, Fischbach PS. Radio-frequency ablation for supraventricular tachycardia in children ≤15 kg is safe and effective. Pediatr Cardiol 2005;26:622-6.
225. Webster G, Margossian R, Alexander ME, Cecchin F, Triedman JK, Walsh EP et al. Impact of transvenous ventricular pacing leads on tricuspid regurgitation in pediatric and congenital heart disease patients. J Interv Card Electrophysiol 2008;21:65-8.
226. Tanel RE, Walsh EP, Triedman JK, Epstein MR, NErgau DM, Saul JP. Five-year experience with radiofrequency catheter ablation: implications for management of arrhythmias in pediatric and young adult patients. J Pediatr 1997;131:878-87.
227. Saul JP, Walsh EP, Triedman JK. Mechanisms and therapy of complex arrhythmias in pediatric patients. J Cardiovasc Electrophysiol 1995;6:1129-48.
228. Kanter RJ. Pearls for ablation in congenital heart disease. J Cardiovasc Electrophy-siol 2010;21:223-30.
229. Cappato R, Schluter M, Weiss C, Antz M, Koschyk DH, Hofmann T, Kick KH. Radiofrequency current catheter ablation of accessory atrioventricular pathways in Ebstein's anomaly. Circulation 1996;94:376-83.
230. Reich JD, Auld D, Hulse E, Sullivan K, Campbell R. The Pediatric Radiofrequency Ablation Registry's experience with Ebstein's anomaly. Pediatric Electrophysi-ology Society. J Cardiovasc Electrophysiol 1998;9:1370-7.
231. Chetaille P, Walsh EP, Triedman JK. Outcomes of radiofrequency catheter ablation of atrioventricular reciprocating tachycardia in patients with congenital heart disease. Heart Rhythm 2004;1:168-73.
232. Bertram H, Bokenkamp R, Peuster M, Hausdorf G, Paul T. Coronary artery stenosis after radiofrequency catheter ablation of accessory atrioventricular pathways in children with Ebstein's malformation. Circulation 2001;103:538-43.
233. Bar-Cohen Y, Cecchin F, Alexander ME, Berul CI, Triedman JK, Walsh EP. Cryoablation for accessory pathways located near normal conduction tissues or within the coronary venous system in children and young adults. Heart Rhythm 2006;3:253-8.
234. Kalman JM, VAnHare GF, Olgin JE, Saxon LA, Stark SI, Lesh MD. Ablation of 'incisional' reentrant atrial tachycardia complicating surgery for congenital heart disease. Use of entrainment to define a critical isthmus of conduction. Circulation 1996;93:502-12.
235. Kanter RJ, Papagiannis J, Carboni MP, Ungerleider RM, Sanders WE, Wharton JM. Radiofrequency catheter ablation of supraventricular tachycardia substrates after mustard and senning operations for d-transposition of the great arteries. J Am Coll Cardiol 2000;35:428-41.
236. Collins KK, Love BA, Walsh EP, Saul JP, Epstein MR, Triedman JK. Location of acutely successful radiofrequency catheter ablation of intraatrial reentrant tachycardia in patients with congenital heart disease. Am J Cardiol 2000;86:969-74.
237. Triedman JK, Alexander ME, Berul CI, Bevilacqua LM, Walsh EP. Electroanatomic mapping of entrained and exit zones in patients with repaired congenital heart disease and intra-atrial reentrant tachycardia. Circulation 2001;103:2060-5.
238. Levine JC, Walsh EP, Saul JP. Radiofrequency ablation of accessory pathways associated with congenital heart disease including heterotaxy syndrome. Am J Cardiol 1993;72:689-93.
239. Triedman JK, DeLucca JM, Alexander ME, BErul CI, Cecchin F, Walsh EP. Prospective trial of electroanatomically guided, irrigated catheter ablation of atrial tachycardia in patients with congenital heart disease. Heart Rhythm 2005; 2:700-5.
240. Tanner H, Lukac P, Schwick N, Fuhrer J, Pedersen AK, Hansen PS et al. Irrigated-tip catheter ablation of intraatrial reentrant tachycardia in patients late after surgery of congenital heart disease. Heart Rhythm 2004;1:268-75.
241. Papagiannis J, Tsoutsinos A, Kirvassilis G, Sofianidou I, Koussi T, Laskari C et al. Nonfluoroscopic catheter navigation for radiofrequency catheter ablation of supraventricular tachycardia in children. Pacing Clin Electrophysiol 2006;29:971-8.
242. Brooks AG, Wilson L, Kuklik P, Stiles MK, John B, Shashidhar et al. Image integration using NavX Fusion: initial experience and validation. Heart Rhythm 2008;5:526-35.
243. Eitel C, Hindricks G, Dagres N, Sommer P, Piorkowski C. EnSite Velocity cardiac mapping system: a new platform for 3D mapping of cardiac arrhythmias. Expert Rev Med Devices 2010;7:185-92.
244. Pflaumer A, Hessling G, Luik A, Wu J, Zrenner B. Remote magnetic catheter mapping and ablation of permanent junctional reciprocating tachycardia in a seven-year-old child. J Cardiovasc Electrophysiol 2007;18:882-5.
245. Wu J, Pflaumer A, Deisenhofer I, Hoppmann P, Hess J, Hessling G. Mapping of atrial tachycardia by remote magnetic navigation in postoperative patients with congenital heart disease. J Cardiovasc Electrophysiol 2010;21:751-9.
246. Klein GJ, Sealy WC, Pritchett EL, Harrison L, Hackel DB, Davis D et al. Cryosur-gical ablation of the atrioventricular node-His bundle: long-term follow-up and properties of the junctional pacemaker. Circulation 1980;61:8-15.
247. Gaita F, Montefusco A, Riccardi R, Giustetto C, Grossi S, Caruzzo E et al. Cryoe-nergy catheter ablation: a new technique for treatment of permanent junctional reciprocating tachycardia in children. J Cardiovasc Electrophysiol 2004;15:263-8.
248. Kirsh JA, Gross GJ, O'Connor S, Hamilton RM. Transcatheter cryoablation of tachyarrhythmias in children: initial experience from an international registry. J Am Coll Cardiol 2005;45:133-6.
249. Miyazaki A, Blaufox AD, Fairbrother DL, Saul JP. Cryo-ablation for septal tachycardia substrates in pediatric patients: mid-term results. J Am Coll Cardiol 2005; 45:581-8.
250. Drago F, De SAntis A, Grutter G, Silvetti MS. Transvenous cryothermal catheter ablation of re-entry circuit located near the atrioventricular junction in pediatric patients: efficacy, safety, and midterm follow-up. J Am Coll Cardiol 2005;45: 1096-103.
251. Papez AL, Al-Ahdab M, Dick M 2nd, Fischbach PS. Transcatheter cryotherapy for the treatment of supraventricular tachyarrhythmias in children: a single center experience. J Interv Card Electrophysiol 2006;15:191-6.
252. Collins KK, Dubin AM, Chiesa NA, Avasarala K, Van Hare GF. Cryoablation versus radiofrequency ablation for treatment of pediatric atrioventricular nodal reentrant tachycardia: initial experience with 4-mm cryocatheter. Heart Rhythm 2006;3:564-70.
253. Drago F, Silvetti MS, De Santis A, Grutter G, Andrew P. Lengthier cryoablation and a bonus cryoapplication is associated with improved efficacy for cryothermal catheter ablation of supraventricular tachycardias in children. J Interv Card Electro-physiol 2006;16:191-8.
254. Silver ES, Silva JN, Ceresnak SR, Chiesa NA, Rhee EK, Dubin AM et al. Cryoabla-tion with an 8-mm tip catheter for pediatric atrioventricular nodal reentrant tachycardia is safe and efficacious with a low incidence of recurrence. Pacing Clin Electrophysiol 2010;33:681-6.
255. Drago F, Russo MS, Silvetti MS, A DES, Iodice F, Naso Onofrio MT. Cryoablation of typical atrioventricular nodal reentrant tachycardia in children: six years' experience and follow-up in a single center. Pacing Clin Electrophysiol 2010;33: 475-81.
256. Czosek RJ, Anderson J, Marino BS, Connor C, Knilans TK. Linear lesion cryoa-blation for the treatment of atrioventricular nodal re-entry tachycardia in pediatrics and young adults. Pacing Clin Electrophysiol 2010;33:1304-11.
257. LaPage MJ, Saul JP, Reed JH. Long-term outcomes for cryoablation of pediatric patients with atrioventricular nodal reentrant tachycardia. Am J Cardiol 2010; 105:1118-21.
258. Fortescue EB, Berul CI, Cecchin F, Walsh EP, Triedman JK, Alexander ME. Patient, procedural, and hardware factors associated with pacemaker lead failures in pediatrics and congenital heart disease. Heart Rhythm 2004;1:150-9.
259. Tomaske M, Gerritse B, Kretzers L, Pretre R, Dodge khatami A, Rahn M et al. A 12-year experience of bipolar steroid-eluting epicardial pacing leads in children. Ann Thorac Surg 2008;85:1704-11.
260. Kammeraad JA, Rosenthal E, Bostock J, Rogers J, Sreeram N. Endocardial pacemaker implantation in infants weighing ≤10 kilograms. Pacing Clin Electrophysiol 2004;27:1466-74.
261. Alexander ME. Transvenous pacing in infants: a faith based initiative? Pacing Clin Electrophysiol 2004;27:1463-5.
262. Pakarinen S, Oikarinen L, Toivonen L. Short-term implantation-related complications of cardiac rhythm management device therapy: a retrospective single-centre 1-year survey. Europace 2010;12:103-8.
263. Bar-Cohen Y, Berul CI, Alexander ME, Fortescue EB, Walsh EP, Triedman JK et al. Age, size, and lead factors alone do not predict venous obstruction in children and young adults with transvenous lead systems. J Cardiovasc Electrophysiol 2006;17:754-9.
264. Baddour LM, Epstein AE, Erickson CC, Knight BP, Levison ME, Lockhart PB et al. Update on cardiovascular implantable electronic device infections and their management: a scientific statement from the American Heart Association. Circulation 2010;121:458-77.
265. Cohen MI, Bush DM, Gaynor JW, Vetter VL, Tanel RE, Rhodes LA. Pediatric pacemaker infections: twenty years of experience. J Thorac Cardiovasc Surg 2002;124:821-7.
266. Khairy P, Landzberg MJ, GAtzoulis MA, Mercier LA, Fernandes SM, Cote JM et al. Transvenous pacing leads and systemic thromboemboli in patients with intracar-diac shunts: a multicenter study. Circulation 2006;113:2391-7.
267. Manolis AS. The deleterious consequences of right ventricular apical pacing: time to seek alternate site pacing. Pacing Clin Electrophysiol 2006;29:298-315.
268. Tantengco MV, Thomas RL, Karpawich PP. Left ventricular dysfunction after long-term right ventricular apical pacing in the young. J Am Coll Cardiol 2001; 37:2093-100.
269. Thambo JB, Bordachar P, Garrigue S, Lafitte S, Sanders P, Reuter S et al. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 2004;110:3766-72.
270. Karpawich PP, Rabah R, Haas JE. Altered cardiac histology following apical right ventricular pacing in patients with congenital atrioventricular block. Pacing Clin Electrophysiol 1999;22:1372-7.
271. Kim JJ, Friedman RA, Eidem BW, Cannon BC, Arora G, Smith EO et al. Ventricular function and long-term pacing in children with congenital complete atrioven-tricular block. J Cardiovasc Electrophysiol 2007;18:373-7.
272. Gebauer RA, Tornek V, Salameh A, MArek J, Chaloupecky V, Gebauer R et al. Predictors of left ventricular remodelling and failure in right ventricular pacing in the young. Eur Heart J 2009;30:1097-104.
273. Peschar M, de Swart H, Michels KJ, Reneman RS, Prinzen FW. Left ventricular septal and apex pacing for optimal pump function in canine hearts. J Am Coll Cardiol 2003;41:1218-26.
274. Vanagt WY, Verbeek XA, Delhaas T, Gewillig M, Mertens L, Wouters P et al. Acute hemodynamic benefit of left ventricular apex pacing in children. Ann Thorac Surg 2005;79:932-6.
275. Gebauer RA, Tomek V, Kubus P, Rasek V, Matejka T, Salameh A et al. Differential effects of the site of permanent epicardial pacing on left ventricular synchrony and function in the young: implications for lead placement. Europace 2009;11: 1654-9.
276. Tomaske M, Breithardt OA, Bauersfeld U. Preserved cardiac synchrony and function with single-site left ventricular epicardial pacing during mid-term follow-up in paediatric patients. Europace 2009;11:1168-76.
277. Tomaske M, Harpes P, Pretre R, Dodge-Khatami A, Bauersfeld U. Long-term experience with AutoCapture-controlled epicardial pacing in children. Europace 2007;9:645-50.
278. Cohen MI, Buck K, Tanel RE, Vetter VL, Rhodes LA, Cox J et al. Capture management efficacy in children and young adults with endocardial and unipolar epi-cardial systems. Europace 2004;6:248-55.
279. Hiippala A, Serwer GA, Clausson E, Davenport L, Brand T, Happonen JM. Automatic atrial threshold measurement and adjustment in pediatric patients. Pacing Clin Electrophysiol 2010;33:309-13.
280. Epstein AE, Dimarco JP, Ellenbogen KA, Estes NA 3rd, Freedman RA, Getters LS et al. ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the ACC/AHA/NASPE 2002 Guideline Update for Implantation of Cardiac Pacemakers and Antiarrhythmia Devices) developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. J Am Coll Cardiol 2008;51:e1-62.
281. Vardas PE, Auricchio A, Blanc JJ, Daubert JC, Drexler H, Ector H et al. Guidelines for cardiac pacing and cardiac resynchronization therapy. The Task Force for Cardiac Pacing and Cardiac Resynchronization Therapy of the European Society of Cardiology. Developed in collaboration with the European Heart Rhythm Association. Europace 2007;9:959-98.
282. Horenstein MS, Karpawich PP. Pacemaker syndrome in the young: do children need dual chamber as the initial pacing mode? Pacing Clin Electrophysiol 2004; 27:600-5.
283. Ragonese P, Guccione P, Drago F, Turchetta A, Calzolari A, Formigari R. Efficacy and safety of ventricular rate responsive pacing in children with complete atrio-ventricular block. Pacing Clin Electrophysiol 1994;17(4 Part 1):603-10.
284. Rosenthal E, Bostock J, Qureshi SA, Baker EJ, Tynan M. Single pass VDD pacing in children and adolescents. Pacing Clin Electrophysiol 1997;20(8 Part 1):1975-82.
285. Kubus P, Materna O, Gebauer RA, Matejka T, Gebauer R, Tláskal T, Janousek J. Permanent epicardial pacing in children: long-term results and factors modifying outcome. Europace 2012;14:509-14.
286. Wilkoff BL, Love CJ, Byrd CL, Bongiorni MG, Carrillo RG, Crossley GH 3rd et al. Transvenous lead extraction: Heart Rhythm Society expert consensus on facilities, training, indications, and patient management: this document was endorsed by the American Heart Association (AHA). Heart Rhythm 2009;6:1085-104.
287. Friedman RA, Van Zandt H, Collins E, LeGras M, Perry J. Lead extraction in young patients with and without congenital heart disease using the subclavian approach. Pacing Clin Electrophysiol 1996;19:778-83.
288. Moak JP, Freedenberg V, Ramwell C, Skeete A. Effectiveness of excimer laser-assisted pacing and ICD lead extraction in children and young adults. Pacing Clin Electrophysiol 2006;29:461-6.
289. Olgun H, Karagoz T, Celiker A, Ceviz N. Patient-and lead-related factors affecting lead fracture in children with transvenous permanent pacemaker. Europace 2008;10:844-47.
290. Cecchin F, Atallah EP, Triedman JK, Alexander ME, BErul CI. Lead extraction in pediatric and congenital heart disease patients. Circ Arrhythm Electrophysiol 2010; 3:437-44.
291. The Antiarrhythmics versus Implantable Defibrillators (AVID) InvestigatorsA comparison of antiarrhythmic-drug therapy with implantable defibrillators in patients resuscitated from near-fatal ventricular arrhythmias. N Engl J Med 1997;337:1576-83.
292. Buxton AE, Lee KL, Fisher JD, Josephson ME, Prytowsky EN, Hafley G. A randomized study of the prevention of sudden death in patients with coronary artery disease. Multicenter Unsustained Tachycardia Trial Investigators. N Engl J Med 1999;341:1882-90.
293. Moss AJ, Zareba W, Hall WJ, Klein H, Wilber DJ, Cannom DS et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med 2002;346:877-83.
294. Bardy GH, Lee KL, Mark DB, Poole JE, Packer DL, Boineau R et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005;352:225-37.
295. Liberthson RR. Sudden death from cardiac causes in children and young adults. N Engl J Med 1996;334:1039-44.
296. Zipes DP, Camm AJ, Borggrefe M, Buxton AE, Chaitman B, Fromer M et al. ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death) developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006;8:746-837.
297. Berul CI, Van Hare GF, Kertesz NJ, Dubin AM, Cecchin F, Collins KK et al. Results of a multicenter retrospective implantable cardioverter-defibrillator registry of pediatric and congenital heart disease patients. J Am Coll Cardiol 2008;51:1685-91.
298. Heersche JH, Blom N, van de Heuvel F, Blank C, Reimer AG, Clur SA et al. Implantable cardioverter defibrillator therapy for prevention of sudden cardiac death in children in the Netherlands. Pacing Clin Electrophysiol 2010;33:179-85.
299. Silka MJ, Kron J, Dunningan A, Dick M 2nd. Sudden cardiac death and the use of implantable cardioverter-defibrillators in pediatric patients. The Pediatric Electrophysiology Society. Circulation 1993;87:800-7.
300. Hamilton RM, Dorian P, Gow RM, Williams WG. Five-year experience with implantable defibrillators in children. Am J Cardiol 1996;77:524-6.
301. Chatrath R, Porter CB, Ackerman MJ. Role of transvenous implantable cardioverter-defibrillators in preventing sudden cardiac death in children, adolescents, and young adults. Mayo Clin Proc 2002;77:226-31.
302. Lawrence D, Von Bergen N, Law IH, Bradley DJ, Dick M 2nd, Frias PA et al. Inappropriate ICD discharges in single-chamber versus dual-chamber devices in the pediatric and young adult population. J Cardiovasc Electrophysiol 2009;20: 287-90.
303. Çeliker A, Olgun H, Karagoz T, Ozer S, Ozkutlu S, Alehan D. Midterm experience with implantable cardioverter-defibrillators in children and young adults. Europace 2010;12:1732-38.
304. Radbill AE, Triedman JK, Berul CI, Fynn-Thompson F, Atallah J, Alexander ME et al. System survival of nontransvenous implantable cardioverter- defibrillators compared to transvenous implantable cardioverter-defibrillators in pediatric and congenital heart disease patients. Heart Rhythm 2010;7:193-8.
305. Kleemann T, Becker T, Doenges K, VAter M, Senges J, Schneider S et al. Annual rate of transvenous defibrillation lead defects in implantable cardioverter-defibrillators over a period of.10 years. Circulation 2007;115:2474-80.
306. Shah MJ. Implantable cardioverter defibrillator-related complications in the pediatric population. Pacing Clin Electrophysiol 2009;32(Suppl 2):S71-4.
307. Stefanelli CB, Bradley DJ, Leroy S, Dick M 2nd, Serwer GA, Fischbach PS. Implantable cardioverter defibrillator therapy for life-threatening arrhythmias in young patients. J Interv Card Electrophysiol 2002;6:235-44.
308. Eicken A, Kolb C, Lange S, Brodherr-Heberlein S, Zrenner B, Schreiber C et al. Implantable cardioverter defibrillator (ICD) in children. Int J Cardiol 2006; 107:30-5.
309. Goldenberg I, Moss AJ, Peterson DR, McNitt S, Zareba W, Andrews ML et al. Risk factors for aborted cardiac arrest and sudden cardiac death in children with the congenital long-QT syndrome. Circulation 2008;117:2184-91.
310. Silka MJ, Bar-Cohen Y. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% should undergo prophylactic implantation of an implantable cardioverter defibrillator. Circ Arrhythm Electrophysiol 2008;1: 298-306.
311. Triedman JK. Should patients with congenital heart disease and a systemic ventricular ejection fraction less than 30% undergo prophylactic implantation of an ICD? Implantable cardioverter defibrillator implantation guidelines based solely on left ventricular ejection fraction do not apply to adults with congenital heart disease. Circ Arrhythm Electrophysiol 2008;1:307-16; discussion 316.
312. Bardy GH, Smith WM, Hood MA, Crozier IG, Melton IC, Jordaens L et al. An entirely subcutaneous implantable cardioverter-defibrillator. N Engl J Med 2010;363:36-44.
313. Griksaitis MJ, Rosengarten JA, Gnanapragasam JP, Haw MP, Morgan JM. Implan-table cardioverter defibrillator therapy in paediatric practice: a single-centre UK experience with focus on subcutaneous defibrillation. Europace 2013;15:523-30.
314. DeMaso DR, Lauretti A, Spieth L, van der Feen JR, Jay KS, Gauvreau K et al. Psy-chosocial factors and quality of life in children and adolescents with implantable cardioverter-defibrillators. Am J Cardiol 2004;93:582-7.
315. Heidbuchel H, Corrado D, Biffi A, Hoffmann E, Panhuyzen-Goedkoop N, Hoogsteen J et al. Recommendations for participation in leisure-time physical activity and competitive sports of patients with arrhythmias and potentially arrhythmogenic conditions. Part II: ventricular arrhythmias, channelopathies and implantable defibrillators. Eur J Cardiovasc Prev Rehabil 2006;13:676-86.
316. Lampert R, Cannom D. Sports participation for athletes with implantable cardioverter-defibrillators should be an individualized risk-benefit decision. Heart Rhythm 2008;5:861-3.
317. Lampert R, Cannom D, Olshansky B. Safety of sports participation in patients with implantable cardioverter defibrillators: a survey of heart rhythm society members. J Cardiovasc Electrophysiol 2006;17:11-5.
318. Maron BJ, Zipes DP. It is not prudent to allow all athletes with implantable-cardioverter defibrillators to participate in all sports. Heart Rhythm 2008;5:864-6.
319. Bristow MR, Saxon LA, Boehmer J, Krueger S, Kass DA, De Marco T et al. Cardiac-resynchronization therapy with or without an implantable defibrillator in advanced chronic heart failure. N Engl J Med 2004;350:2140-50.
320. Cleland JG, Daubert JC, Erdmann E, Freemantle N, Gras D, Kappenberger L et al. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-49.
321. Linde C, Abraham WT, Gold MR, St John Sutton M, Ghio S, Daubert C. Randomized trial of cardiac resynchronization in mildly symptomatic heart failure patients and in asymptomatic patients with left ventricular dysfunction and previous heart failure symptoms. J Am Coll Cardiol 2008;52:1834-43.
322. Moss AJ, Hall WJ, Cannom DS, Klein H, Brown MW, Daubert JP et al. Cardiac-resynchronization therapy for the prevention of heart-failure events. N Engl J Med 2009;361:1329-38.
323. Dubin AM, Janousek J, Rhee E, Strieper MJ, Cecchin F, Law IH et al. Resynchro-nization therapy in pediatric and congenital heart disease patients: an international multicenter study. J Am Coll Cardiol 2005;46:2277-83.
324. Janousek J, Gebaouer RA, Abdul-Khaliq H, Turner M, Kornyei L, Grollmuss O et al. Cardiac resynchronisation therapy in paediatric and congenital heart disease: differential effects in various anatomical and functional substrates. Heart 2009;95:1165-71.
325. Cecchin F, Frangini PA, Brown DW, Fynn-Thompson F, Alexander ME, Triedman JK et al. Cardiac resynchronization therapy (and multisite pacing) in pediatrics and congenital heart disease: five years experience in a single institution. J Cardiovasc Electrophysiol 2009;20:58-65.
326. Janousek J, Gebauer RA. Cardiac resynchronization therapy in pediatric and congenital heart disease. Pacing Clin Electrophysiol 2008;31(Suppl 1):S21-3.
327. Janousek J, Tomek V, Chaloupecky VA, Reich O, Gebauer RA, Kautzner J et al. Cardiac resynchronization therapy: a novel adjunct to the treatment and prevention of systemic right ventricular failure. J Am Coll Cardiol 2004;44:1927-31.
328. Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J et al. Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC Guidelines for cardiac and resyn-chronization therapy. Europace 2010;12:1526-36.
329. Rhee EK, Canter CE, Basile S, Webber SA, Naftel DC. Sudden death prior to pediatric heart transplantation: would implantable defibrillators improve outcome? J Heart Lung Transplant 2007;26:447-52.
330. Chung ES, Leon AR, Tavazzi L, Sun JP, Nihoyannopoulos P, Merlino et al. Results of the Predictors of Response to CRT (PROSPECT) trial. Circulation 2008;117:2608-16.
331. Gorcsan J III, Abraham T, Agler DA, Bax JJ, Derumeaux G, Grimm Ra et al. Echo-cardiography for cardiac resynchronization therapy: recommendations for performance and reporting-a report from the American Society of Echocardiography Dyssynchrony Writing Group endorsed by the Heart Rhythm Society. J Am Soc Echocardiogr 2008;21:191-213.
332. Marsan NA, Bleeker GB, Ypenburg C, Ghio S, van de Veire NR, Holman ER et al. Real-time three-dimensional echocardiography permits quantification of left ventricular mechanical dyssynchrony and predicts acute response to cardiac resynchronization therapy. J Cardiovasc Electrophysiol 2008;19:392-9.